81 related articles for article (PubMed ID: 19795452)
1. Targeting slow-proliferating ovarian cancer cells.
Kondoh E; Mori S; Yamaguchi K; Baba T; Matsumura N; Cory Barnett J; Whitaker RS; Konishi I; Fujii S; Berchuck A; Murphy SK
Int J Cancer; 2010 May; 126(10):2448-56. PubMed ID: 19795452
[TBL] [Abstract][Full Text] [Related]
2. Targeting Dormant Ovarian Cancer Cells
Huang Z; Kondoh E; Visco ZR; Baba T; Matsumura N; Dolan E; Whitaker RS; Konishi I; Fujii S; Berchuck A; Murphy SK
Mol Cancer Ther; 2021 Jan; 20(1):85-95. PubMed ID: 33037137
[TBL] [Abstract][Full Text] [Related]
3. UCN-01 (7-hydroxystaurosporine) induces apoptosis and G1 arrest of both primary and metastatic oral cancer cell lines in vitro.
Otsubo A; Bhawal UK; Nomura Y; Mitani Y; Ozawa K; Kuniyasu H; Sugiyama M
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):391-7. PubMed ID: 17321452
[TBL] [Abstract][Full Text] [Related]
4. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer.
Kim M; Park IY; Lim J; Kim Y; Han KT; Chung WH; Han K
Ann Clin Lab Sci; 2006; 36(4):455-60. PubMed ID: 17127735
[TBL] [Abstract][Full Text] [Related]
5. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
[TBL] [Abstract][Full Text] [Related]
6. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
[TBL] [Abstract][Full Text] [Related]
7. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
10. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
11. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
[TBL] [Abstract][Full Text] [Related]
12. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
15. [Expression of connexin 43 in ovarian cancer and its relationship with chemoresistance].
Li X; Liao QP
Zhonghua Fu Chan Ke Za Zhi; 2009 Jan; 44(1):50-5. PubMed ID: 19563063
[TBL] [Abstract][Full Text] [Related]
16. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
17. Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer.
McGrogan B; Phelan S; Fitzpatrick P; Maguire A; Prencipe M; Brennan D; Doyle E; O'Grady A; Kay E; Furlong F; McCann A
Hum Pathol; 2014 Jul; 45(7):1509-19. PubMed ID: 24792619
[TBL] [Abstract][Full Text] [Related]
18. [Effect of aurora kinase B inhibitor AZD1152 in the treatment of cisplatin-resistant ovarian carcinoma].
Ma YX; Li XZ
Zhonghua Fu Chan Ke Za Zhi; 2013 Jan; 48(1):46-50. PubMed ID: 23531251
[TBL] [Abstract][Full Text] [Related]
19. Aurora-B protein expression is linked to initial response to taxane-based first-line chemotherapy in stage III ovarian carcinoma.
Beussel S; Hasenburg A; Bogatyreva L; Hauschke D; Werner M; Lassmann S
J Clin Pathol; 2012 Jan; 65(1):29-35. PubMed ID: 22011448
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors.
Sui M; Chen F; Chen Z; Fan W
Int J Cancer; 2006 Aug; 119(3):712-7. PubMed ID: 16496381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
